Loading...
XNAS
SVRA
Market cap1.29bUSD
Jul 09, Last price  
6.29USD
1D
-1.41%
1Q
11.13%
Jan 2017
3.52%
IPO
-99.82%
Name

Savara Inc

Chart & Performance

D1W1MN
XNAS:SVRA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
30.26%
Rev. gr., 5y
25.99%
Revenues
0k
0500,000500,000300,000488,9590001,54854400,000000257,00000000
Net income
-119m
L+23.94%
-29,331,773-22,142,040-26,647,493-11,325,058-8,450,922-13,260,000-15,559,489-21,480,285-28,702,000-39,842,000-10,923,000-29,797,000-61,516,000-78,173,000-49,615,000-43,014,000-38,150,000-54,698,000-95,881,000-118,837,000
CFO
-101m
L+13.41%
-15,773,544-19,643,190-23,787,604-12,616,416-8,341,237-13,466,954-13,918,868-17,788,962-24,645,000-32,949,000-8,370,000-28,234,000-39,275,000-45,123,000-39,836,000-40,081,000-34,554,000-51,061,000-89,088,000-101,037,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
URL
http://savarapharma.com/
IPO date
Jun 25, 2001
Employees
28
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT